Eletriptan provides consistent migraine relief: results of a within-patient multiple-dose study

  • M Almas
  • S Tepper
  • S Landy
  • E Ramos
Open Access
Poster presentation
  • 410 Downloads

Keywords

Placebo Migraine Migraine Attack Eletriptan Migraine Treatment 

Objective

To evaluate the consistency of response to eletriptan in migraine.

Background

Surveys indicate that more than 40% of individuals have an average headache frequency of 2 or more attacks per month. Lack of consistent response has been cited in patient surveys as one of the top 3 reasons for dissatisfaction with migraine treatments.

Methods

Patients first completed an open-label, lead-in period in which they treated 3 migraine attacks with eletriptan 40 mg. Based on response to open-label treatment, patients were treated with either eletriptan 40 mg (E40; N=539) or eletriptan 80 mg (E80; N=432) in a 4-attack consistency of response study in which placebo was substituted, in a randomized, double-blind fashion, for the treatment of one attack. Headache response was defined as improvement at 2 hours post-dose to a headache intensity of none (pain-free) or mild. Within-patient consistency was defined a priori as headache response at 2 hours on at least 2 out of 3 attacks.

Results

During double-blind treatment, within-patient consistency was 77% for E40 and 73% for E80. For patients (N=47) who had responded to 0/3 attacks on E40 in the open-label phase, titration to the E80 dose resulted in headache response in 55%. A repeated measures logistic regression analysis found that sustained headache response at 24 hours, averaged across 3 attacks, was significantly higher on both E40 vs. placebo (49% vs. 32%; p < 0.001) and E80 vs. placebo (43% vs. 11%; p < 0.001). Sustained pain-free at 24 hours, averaged across all 3 attacks, was also significantly higher on both E40 vs. placebo (30% vs. 5%; p < 0.001) and E80 vs. placebo (25% vs. 3%; p < 0.001).

Conclusion

Eletriptan showed consistent and sustained efficacy in the treatment of migraine. Funded by Pfizer Inc.

Copyright information

© Almas et al; licensee Springer. 2013

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Authors and Affiliations

  • M Almas
    • 1
  • S Tepper
    • 2
  • S Landy
    • 3
  • E Ramos
    • 1
  1. 1.Pfizer IncUSA
  2. 2.Cleveland ClinicUSA
  3. 3.Wesley Neurology and Headache ClinicUSA

Personalised recommendations